lilly_entrance_web

Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population

pharmafile | May 13, 2019 | News story | Sales and Marketing |  Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma 

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a single agent for the treatment of hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been previously treated with Bayer’s Nexavar (sorafenib), the FDA has confirmed.

In a study of 292 patients in this indication, it was demonstrated that Cyramza, when combined with best supportive care (BSC) and administered every two weeks, improved median overall survival by 8.5 months, compared to 7.3 months  with placebo plus BSC.

Overall survival was the study’s primary endpoint, and the results of the trial succeeded in meeting the FDA’s criteria for the drug to be approved. The recommended dose is 8mg/kg administered intravenously every fortnight.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

The Gateway to Local Adoption Series

Latest content